Dashboard
Manage Tickers

IPHA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

this-progressive-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Progressive Analyst Is No Longer Bull...
09/18/2025 14:00:34

alphabet-to-rally-more-than-14-here-are-10-top-analyst-forecasts-for-thursday
Alphabet To Rally More Than 14%? Here Are ...
09/18/2025 12:16:40

leerink-partners-downgrades-innate-pharma-to-market-perform-lowers-price-target-to-2
Leerink Partners Downgrades Innate Pharma ...
09/18/2025 11:11:32

Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers...

hc-wainwright--co-downgrades-innate-pharma-to-neutral
HC Wainwright & Co. Downgrades Innate Phar...
09/18/2025 10:23:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) from Buy to Neutral.

Core News & Articles
Earnings Scheduled For September 17, 2025
09/17/2025 08:32:11

innate-pharma-h1-eps-028-up-from-034-yoy-sales-551m-down-from-1335m-yoy
Innate Pharma H1 EPS $(0.28) Up From $(0.3...
09/17/2025 05:50:37

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
07/18/2025 12:07:40

innate-pharma-presents-iph6501-preclinical-data-at-eha-2025-highlighting-potential-in-relapsed-refractory-and-untreated-cd20-b-nhl
Innate Pharma Presents IPH6501 Preclinical...
06/13/2025 06:28:24

Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro...

innate-pharma-highlights-long-term-clinical-benefit-of-lacutamab-in-szary-syndrome-and-mycosis-fungoides-at-asco-2025
Innate Pharma Highlights Long-Term Clinica...
05/23/2025 05:41:56

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented a...

innate-pharma-highlights-continued-oncology-advancements-at-asco-2025-with-lacutamab-iph4502-and-astrazenecas-neocoast-2-data
Innate Pharma Highlights Continued Oncolog...
05/19/2025 06:37:30

Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoidesTrial in Progress poster on IPH45...

innate-pharma-announces-selection-of-iph6501-anket-abstract-for-eha-2025-emphasizing-novel-nk-cell-engagement-strategy
Innate Pharma Announces Selection Of IPH65...
05/15/2025 07:03:00

innate-pharma-reports-q1-revenue-of-12m-725m-cash-position-excluding-15m-sanofi-investment-highlights-progress-across-anket-and-adc-programs-with-runway-to-mid-2026
Innate Pharma Reports Q1 Revenue Of €1.2M,...
05/13/2025 05:56:11

Core News & Articles
Innate Pharma Presents New Preclinical Dat...
04/29/2025 19:03:17

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced sol...

french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit
French Drugmaker Sanofi Clocks 20% Q1 Prof...
04/24/2025 14:03:30

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 gu...

hc-wainwright--co-reiterates-buy-on-innate-pharma-lowers-price-target-to-11
HC Wainwright & Co. Reiterates Buy on Inna...
04/24/2025 11:08:24

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and lowers the pric...

Core News & Articles
Innate Pharma Confirms €15M Capital Increa...
04/24/2025 05:51:16

Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeti...

Core News & Articles
Innate Pharma Regains SAR'579 Rights For A...
04/23/2025 05:45:35

Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR'579) /IPH6101 currently in development for AMLPotentia...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION